Key result
Routine use of blood-based biomarkers like BNP and troponin for decision making in heart failure faces hurdles for precise risk stratification, driving research into biomarker cocktails.
Answers are grounded in this paper and cite their sources.
Discusses the potential and challenges of using serial natriuretic peptide measurements and multi-biomarker approaches for precision risk stratification in heart failure.
Heart failure (HF) is a major worldwide epidemic associated with high morbidity and mortality, with the number of cases expected to increase in line with increasing average life expectancy (1). Progressive advances in medical science have allowed identification of blood-based biomarkers [e.g., B-type natriuretic peptide (BNP), N-terminal prohormone of BNP (NT-proBNP) and troponin] that are able to provide improved prognostic information for patients at risk of or following an HF event. However, their routine use for decision making at times is limited and shows challenging hurdles for precise risk stratification, such as emerging risks being affiliated with sub-clinical myocardial damage for use of troponin and/or inflammatory biomarkers (2) driving researchers to investigate a cocktail of biomarkers to improve risk prediction.
No takes yet. Share an insight, caveat, or question.
Israr et al. (2017) conducted a review in Heart failure. Serial measurements of natriuretic peptide and other biomarkers was evaluated. Routine use of blood-based biomarkers like BNP and troponin for decision making in heart failure faces hurdles for precise risk stratification, driving research into biomarker cocktails.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: